indemnification agreementIndemnification Agreement • November 7th, 2024 • Pharma Two B Ltd. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of __________, 2024, is entered into by and between Pharma Two B Ltd., an Israeli company whose address is 12 Shaul Hamelech St., Kiryat Ono, 5565420, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page hereto officer (the “Indemnitee”).
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • November 1st, 2024 • Pharma Two B Ltd. • Pharmaceutical preparations
This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of August 27, 2024 (the “Effective Date”), by and between Pharma Two B Ltd., an Israeli company number 513958371 (the “Company”), and Dan Teleman, Israeli I.D. [*****] (the “Executive” and collectively with the Company, the “Parties”).
ContractEmployment Agreement • October 15th, 2024 • Pharma Two B Ltd. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed
EMPLOYMENT AGREEMENT dated: April 18,2023Employment Agreement • November 1st, 2024 • Pharma Two B Ltd. • Pharmaceutical preparations
The Executive shall be granted an option to purchase such number of Preferred F-3 Shares of the Company, equal to 2% of the Company’s share capital on a fully diluted basis as of the date hereof (the “Shares”), subject to any dilution, and under the following terms and conditions. The Shares shall have the rights and obligations set forth in the Company’s Articles of Association, which shall be amended to provide for the authorization and creation of the series of the Shares. The option will be subject to the following vesting - 25% of the Shares underlying the option will vest on the first anniversary of the date of grant and the remaining 75% will vest in 36 equal monthly installments thereafter, provided that any unvested part of the option will vest and become immediately exercisable upon consummation of a Change in Control or Qualified Change in Control (as defined below).
Consulting AgreementConsulting Agreement • October 15th, 2024 • Pharma Two B Ltd. • Pharmaceutical preparations
This Consulting Agreement, dated effective on June 16, 2024 (“Agreement”), is made and entered into by and between Pharma Two B Ltd., a company incorporated under the laws of the state of Israeli and having its registered office at 4 Oppenheimer St. Haogen B, Weizmann Science Park Rehovot, Israel (“Company”) and Lankry Consulting Services, [*****] (“Consultant”).
